SK Biopharmaceuticals Co Ltd

Common Name
SK Biopharmaceuticals
Country
South Korea
Sector
Healthcare
Industry
Biotechnology
Employees
246
Ticker
326030
Exchange
KOREA EXCHANGE
Description
Sk Biopharmaceuticals Co., Ltd. is a leading biomedical company primarily engaged in the research, development, and commercialization of innovative pharmaceutical products. This company operates with ...

SK Biopharmaceuticals's Climate Target Data Preview

As of 2024, SK Biopharmaceuticals has disclosed 2 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 2 absolute reduction targets, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into SK Biopharmaceuticals ’s climate strategy, ambition level, and alignment with global decarbonization goals.

Target TypeScope of TargetUnitTargetTarget Year
Absolute-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e)
Copy restricted. Please purchase to unlock this data.
a
2026
Absolute-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e)
Copy restricted. Please purchase to unlock this data.
a
2030
Download SK Biopharmaceuticals's Climate Targets data for free

Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.

Verified Sources Behind SK Biopharmaceuticals’s Climate Targets Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore SK Biopharmaceuticals’s data sources below and access millions more through our Disclosure Search.

a. SK Biopharmaceuticals's Sustainability Report 2024
Trace every data point back to SK Biopharmaceuticals’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Insights into SK Biopharmaceuticals's Greenhouse Gas Emissions Pathways

As of 2024, SK Biopharmaceuticals has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions. a

Does SK Biopharmaceuticals have a target to reduce the emissions from its operations?

As of 2024, SK Biopharmaceuticals has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources. a

SK Biopharmaceuticals's most ambitious operational target is to reduce these emissions by 50% by 2030, compared to a baseline of 1,341 Metric Tonnes of CO2 equivalent (mtCO2e) in 2020. a

Instead of reducing operational emissions, SK Biopharmaceuticals has increased them, with 2023 levels exceeding those of the 2020 baseline, placing the company well behind its reduction target. a

SK Biopharmaceuticals's Operational (Scope 1+2) Emissions Pathway

202020232026203004008001.2 k1.6 kCurrent (+10%)Target 2026 (-30%)Target 2030 (-50%)
Want Full Access to SK Biopharmaceuticals's Climate Targets Dataset?
Sign Up